Skip to content
- A novel germline mutation of TP53 with breast cancer diagnosed as Li-Fraumeni syndrome.
- Kai M, Kubo M, Shikada S, Hayashi S, Morisaki T, Yamada M, Takao Y, Shimazaki A, Harada Y, Kaneshiro K, Mizuuchi Y, Shindo K, Nakamura M.
- Surg Case Rep. 2022 Oct 11;8(1):197. doi: 10.1186/s40792-022-01546-y.
- Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations.
- Dietrich M, Ball E, McKenzie A, Vidal G.
- OncLive. Peer Exchange. 2022 Oct 10.
- Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
- Miller RE, Elyashiv O, El-Shakankery KH, Ledermann JA.
- Onco Targets Ther. 2022 Oct 4;15:1105-1117. doi: 10.2147/OTT.S272199.